Covagen AG is acquired by an affiliate of Janssen Pharmaceutical which belongs to Johnson & Johnson. Covagen AG, located in Schlieren near Zurich, is a privately-held, biopharmaceutical company specializing in the development of multispecific protein therapeutics through FynomAb® by fusing fully human Fynomer binding proteins to antibodies. Covagen was co-founded in 2007 by Julian Bertschinger and Dragan Grabulovski as a spin-off company of ETH Zurich, Switzerland. VISCHER has been assisting Covagen in its inception, has been advising Covagen in all its financing rounds as well as major collaborations and has now acted for Covagen for Swiss law matters in its sale. The team is lead by Matthias Staehelin with Ruben Masar (Corporate), Nadia Tarolli (Tax) and Melanie Knüsel (Tax).